HUMAN COMPLEMENT FACTOR H RELATED PROTEIN TEST FOR MONITORING BLADDER CANCER
2001; Lippincott Williams & Wilkins; Volume: 165; Issue: 2 Linguagem: Inglês
10.1097/00005392-200102000-00005
ISSN1527-3792
AutoresMika Raitanen, Timo Marttila, Martti Nurmi, Martti Ala‐Opas, Pentti Nieminen, Risto Aine, Teuvo L.J. Tammela,
Tópico(s)Bladder and Urothelial Cancer Treatments
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Feb 2001HUMAN COMPLEMENT FACTOR H RELATED PROTEIN TEST FOR MONITORING BLADDER CANCER MIKA-P. RAITANEN, TIMO MARTTILA, MARTTI NURMI, MARTTI ALA-OPAS, PENTTI NIEMINEN, RISTO AINE, TEUVO L.J. TAMMELA, and FINNBLADDER GROUP† MIKA-P. RAITANENMIKA-P. RAITANEN , TIMO MARTTILATIMO MARTTILA , MARTTI NURMIMARTTI NURMI , MARTTI ALA-OPASMARTTI ALA-OPAS , PENTTI NIEMINENPENTTI NIEMINEN , RISTO AINERISTO AINE , TEUVO L.J. TAMMELATEUVO L.J. TAMMELA , and FINNBLADDER GROUP† View All Author Informationhttps://doi.org/10.1097/00005392-200102000-00005AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The BTA stat‡ Bion Diagnostic Sciences, Inc., Redmond, Washington. test is a rapid, noninvasive, qualitative urine test that detects bladder tumor associated antigen (human complement factor H related protein) in urine. We compared BTA stat test to voided urine cytology in patients monitored for bladder cancer in a prospective trial, and determined whether this test is effective in detection of recurrence not seen by regular cystoscopy. Materials and Methods: A total of 445 consecutive patients with bladder cancer were studied. A voided urine sample was obtained before cystoscopy and divided for culture, cytology and BTA stat testing. In cases of a positive BTA stat test but negative cystoscopy, excretory urography or renal ultrasound, random biopsies and collected ureteral urine samples for ureteral cytology were obtained. The overall sensitivity and specificity as well as positive and negative predictive values for BTA stat test, cytology and their combination were calculated. Results: Of the 445 patients 118 (26.5%) had bladder cancer recurrence on cystoscopy, which was detected by BTA stat test and cytology in 63 (53.4%) and 21 (17.8%), respectively. Of the remaining 327 patients not having recurrent tumor on cystoscopy 81 (24.8%) had a positive BTA stat test. Excretory urography or renal ultrasound and random biopsies in 48 (59.3%) of these patients revealed 7 recurrences, making the total number of recurrent tumors 125 of 412 (30.3%). The overall sensitivities and specificities for the BTA stat test, cytology and their combination were 56.0%, 19.2%, 60.0% and 85.7%, 98.3% and 85.0%, respectively. Conclusions: The sensitivity for detection of recurrent tumor on BTA stat test is superior to that of voided urine cytology in all bladder cancer categories, whereas the specificity of voided urine cytology is higher than that for BTA stat test. However, a sixth of the patients with apparent false-positive BTA stat test results chosen for further investigation had recurrent tumors that were not found on routine cystoscopy. Although the sensitivity and specificity were highest when both tests were used, the differences were not significant overall. Therefore, the BTA stat test could potentially replace urine cytology for followup of superficial bladder cancer. References 1 : Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol1990; 21: 886. Google Scholar 2 : Accuracy of cytological diagnosis of cancer of the urinary tract. Acta Cytol1964; 8: 186. Google Scholar 3 : Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology1997; 50: 349. Google Scholar 4 : Specificity of human complement factor H-related protein test (BARD BTA stat test). Scand J Urol Nephrol1999; 33: 234. Google Scholar 5 : Noninvasive detection of bladder cancer with the BTA stat test. J Urol1999; 161: 443. Link, Google Scholar 6 : Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol1999; 35: 52. Google Scholar 7 : Urine sediment smears. A diagnostic procedure in cancers of the urinary tract. Science1945; 101: 519. Google Scholar 8 Mostofi, F. K., Sobin, L. H. and Torloni, H.: Histological Typing of Urinary Bladder tumours. Presented at World Health Organization, Geneva, 1973 Google Scholar 9 : TNM Classification of Malignant Tumours. Geneva: International Union Against Cancer1978. Google Scholar 10 : Sensitivity of human complement factor H related protein (BTA Stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol2000; 163: 1689. Abstract, Google Scholar 11 : Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol1982; 54: 152. Google Scholar 12 : Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol1982; 127: 250. Link, Google Scholar 13 : Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?. Br J Urol1995; 75: 193. Google Scholar 14 : Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol1993; 149: 1010. Link, Google Scholar 15 : Occurrence of uroepithelial tumors of the upper urinary tract after the initial diagnosis of bladder cancer. J Urol1988; 140: 745. Link, Google Scholar 16 : Comparison of bladder washings and urine cytology in the diagnosis of bladder cancer. J Urol1973; 110: 664. Link, Google Scholar From the Division of Urology and Department of Pathology, Tampere University Hospital and Medical School, University of Tampere, Tampere, Department of Surgery, Seinäjoki Hospital, Seinäjoki, Division of Urology, Turku University Hospital, Turku, Division of Urology, Kuopio University Hospital, Kuopio, and Medical Informatics Group and University of Oulu, Oulu, Finland© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byATSÜ N, EKICI S, ÖGE Ö, ERGEN A, HASÇELIK G and ÖZEN H (2018) FALSE-POSITIVE RESULTS OF THE NMP22 TEST DUE TO HEMATURIAJournal of Urology, VOL. 167, NO. 2 Part 1, (555-558), Online publication date: 1-Feb-2002. Volume 165Issue 2February 2001Page: 374-377 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsmonitoring, physiologicbladder neoplasmstumor markers, biologicalcytologyMetricsAuthor Information MIKA-P. RAITANEN More articles by this author TIMO MARTTILA More articles by this author MARTTI NURMI More articles by this author MARTTI ALA-OPAS More articles by this author PENTTI NIEMINEN More articles by this author RISTO AINE More articles by this author TEUVO L.J. TAMMELA More articles by this author FINNBLADDER GROUP† Participants: M. Ala-Opas and K. Tuhkanen, Kuopio University Hospital; T. Forssel, Kymenlaakso Central Hospital; P. Granbacka and C. Palmberg, Pietarsaari Hospital; T. Liukkonen, Mikkeli Central Hospital; H. Juusela, Jorvi Hospital; H. Korhonen, Satakunta Central Hospital; P. Hellström and O. Lukkarinen, Oulu University Hospital; M. Nurmi and P. Rajala, Turku University Hospital; J. Permi and V.-M. Puolakka, Lappeenranta Central Hospital; M. Talja, Päijät-Häme Central Hospital; T. Tammela and M.-P. Raitanen, Tampere University Hospital; M. Leppilahti, M. Leskinen and T. Marttila, Seinäjoki Central Hospital; E. Kaasinen, Hyvinkää District Hospital; J. Ervasti, Ähtäri Hospital; A. Mehik, Oulainen Hospital; R. Kauppinen and M. Rauvala, Rovaniemi Central Hospital; J. Viitanen, Pohjois-Karjala Central Hospital; and E. Hansson and P. Nylund, Vaasa Central Hospital. More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)